Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of “Hold” from Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have received a consensus recommendation of “Hold” from the five brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $19.3333.

Several research firms recently weighed in on CARL. Zacks Research raised Carlsmed from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 26th. Truist Financial dropped their price target on Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. The Goldman Sachs Group dropped their price target on Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. BTIG Research reiterated a “buy” rating and set a $23.00 price objective on shares of Carlsmed in a research report on Wednesday, May 6th. Finally, Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th.

Carlsmed Stock Performance

NASDAQ CARL opened at $11.07 on Friday. Carlsmed has a 1-year low of $8.50 and a 1-year high of $17.19. The company has a market capitalization of $300.88 million and a P/E ratio of -4.41. The business has a 50 day moving average price of $10.36 and a 200 day moving average price of $11.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.88 and a quick ratio of 11.67.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%.The firm had revenue of $16.12 million during the quarter. Sell-side analysts expect that Carlsmed will post -1.35 EPS for the current fiscal year.

Institutional Trading of Carlsmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC purchased a new stake in Carlsmed during the 3rd quarter worth about $16,772,000. Janus Henderson Group PLC increased its position in Carlsmed by 7.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after purchasing an additional 86,834 shares in the last quarter. Vanguard Group Inc. purchased a new stake in Carlsmed during the 3rd quarter worth about $3,042,000. KCM Capital Inc purchased a new stake in Carlsmed during the 1st quarter worth about $1,810,000. Finally, TD Waterhouse Canada Inc. increased its position in Carlsmed by 15.2% during the 4th quarter. TD Waterhouse Canada Inc. now owns 175,405 shares of the company’s stock worth $2,154,000 after purchasing an additional 23,163 shares in the last quarter.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).